Mikio Mikami

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5982628/publications.pdf

Version: 2024-02-01

94 papers 1,990 citations

257101 24 h-index 288905 40 g-index

96 all docs 96 docs citations

96 times ranked 2226 citing authors

#	Article	IF	CITATIONS
1	A retrospective study for investigating the outcomes of endometrial cancer treated with radiotherapy. International Journal of Gynecology and Obstetrics, 2022, 156, 262-269.	1.0	1
2	Impact of COVID-19 on gynecologic cancer treatment in Japan: a nationwide survey by the Japan Society of Gynecologic Oncology (JSGO). Journal of Gynecologic Oncology, 2022, 33, .	1.0	9
3	Sensitive New Assay System for Serum <i>Wisteria floribunda</i> Agglutinin-Reactive Ceruloplasmin That Distinguishes Ovarian Clear Cell Carcinoma from Endometrioma. Analytical Chemistry, 2022, 94, 2476-2484.	3.2	3
4	Significance of histology and nodal status on the survival of women with early-stage cervical cancer: validation of the 2018 FIGO cervical cancer staging system. Journal of Gynecologic Oncology, 2022, 33, .	1.0	0
5	Survival and reproductive outcomes after fertilityâ€sparing surgery performed for borderline epithelial ovarian tumor in Japanese adolescents and young adults: Results of a retrospective nationwide study. Journal of Obstetrics and Gynaecology Research, 2022, 48, 806-816.	0.6	6
6	Impact of <scp>COVID</scp> â€19 on cervical cancer screening in Japan: A survey of populationâ€based screening in urban Japan by the Japan Society of Gynecologic Oncology. Journal of Obstetrics and Gynaecology Research, 2022, 48, 757-765.	0.6	7
7	Sentinel node navigation surgery in cervical cancer: a systematic review and metaanalysis. International Journal of Clinical Oncology, 2022, 27, 1247-1255.	1.0	6
8	Risk assessment in the patients with uterine cervical cancer harboring intermediate risk factors after radical hysterectomy: a multicenter, retrospective analysis by the Japanese Gynecologic Oncology Group. International Journal of Clinical Oncology, 2022, 27, 1507-1515.	1.0	6
9	The Role of Hypertension and Renin-angiotensin-aldosterone System Inhibitors in Bleomycin-induced Lung Injury. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e321-e327.	0.2	4
10	Utility of the 3-tier grouping system for survival discriminatory ability in stage IIA cervical cancer. European Journal of Surgical Oncology, 2021, 47, 331-337.	0.5	O
11	The trend and outcome of postsurgical therapy for high-risk early-stage cervical cancer with lymph node metastasis in Japan: a report from the Japan Society of Gynecologic Oncology (JSGO) guidelines evaluation committee. Journal of Gynecologic Oncology, 2021, 32, e44.	1.0	7
12	Association of menopause, aging and treatment procedures with positive margins after therapeutic cervical conization for CIN 3: a retrospective study of 8,856 patients by the Japan Society of Obstetrics and Gynecology. Journal of Gynecologic Oncology, 2021, 32, e68.	1.0	13
13	Impact of lymphadenectomy on the treatment of endometrial cancer using data from the JSOG cancer registry. Obstetrics and Gynecology Science, 2021, 64, 80-89.	0.6	5
14	Surgical margin status and recurrence pattern in invasive vulvar Paget's disease: A Japanese Gynecologic Oncology Group study. Gynecologic Oncology, 2021, 160, 748-754.	0.6	10
15	A randomized phase III trial of adjuvant chemotherapy versus concurrent chemoradiotherapy for postoperative cervical cancer: Japanese Gynecologic Oncology Group study (JGOG1082). International Journal of Gynecological Cancer, 2021, 31, 623-626.	1.2	12
16	Wait-time for adjuvant radiotherapy and oncologic outcome in early-stage cervical cancer: A treatment implication during the coronavirus pandemic. European Journal of Cancer, 2021, 148, 117-120.	1.3	9
17	The validity of the subsequent pregnancy index score for fertility-sparing trachelectomy in early-stage cervical cancer. Fertility and Sterility, 2021, 115, 1250-1258.	0.5	6
18	Clinico-pathological characteristics of patients with stage IB1–IB2 (FIGO 2018) uterine cervical cancer: a nationwide study in Japan. International Journal of Clinical Oncology, 2021, 26, 1541-1552.	1.0	4

#	Article	IF	Citations
19	Characteristics and outcomes of women with adenocarcinoma versus squamous cell carcinoma of the vulva: A Japanese Gynecologic Oncology Group study. European Journal of Surgical Oncology, 2021, 47, 3188-3193.	0.5	1
20	Surveillance of radical hysterectomy for early-stage cervical cancer in the early experienced period of minimally invasive surgery in Japan. International Journal of Clinical Oncology, 2021, 26, 2318-2330.	1.0	3
21	Hospital volume-outcome relationship in vulvar cancer treatment: a Japanese Gynecologic Oncology Group study. Journal of Gynecologic Oncology, 2021, 32, e24.	1.0	3
22	The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. Journal of Gynecologic Oncology, 2021, 32, e49.	1.0	26
23	Identification of Tumor Antigens in Ovarian Cancers Using Local and Circulating Tumor-Specific Antibodies. International Journal of Molecular Sciences, 2021, 22, 11220.	1.8	3
24	Association between hospital treatment volume and survival of women with gynecologic malignancy in Japan: a JSOG tumor registry-based data extraction study. Journal of Gynecologic Oncology, 2021, 33, .	1.0	4
25	Comparison of treatment outcomes of surgery and radiotherapy, including concurrent chemoradiotherapy for stage lb2-llb cervical adenocarcinoma patients: a retrospective study. Journal of Gynecologic Oncology, 2021, 33, .	1.0	1
26	Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2020, 46, 868-875.	0.5	24
27	Fertility-sparing trachelectomy for early-stage cervical cancer: A proposal of an ideal candidate. Gynecologic Oncology, 2020, 156, 341-348.	0.6	22
28	Investigation of clinicopathological features of vulvar cancer in 1068 patients: A Japanese Gynecologic Oncology Group (JGOG) nationwide survey study. Gynecologic Oncology, 2020, 159, 449-455.	0.6	5
29	Epidemiological guideline influence on the therapeutic trend and patient outcome of uterine cervical cancer in Japan: Japan society of gynecologic oncology guideline evaluation committee project. Gynecologic Oncology, 2020, 159, 248-255.	0.6	11
30	Comprehensive Serum Glycopeptide Spectra Analysis Combined with Artificial Intelligence (CSGSA-AI) to Diagnose Early-Stage Ovarian Cancer. Cancers, 2020, 12, 2373.	1.7	12
31	Utility of Comprehensive Serum Glycopeptide Spectra Analysis (CSGSA) for the Detection of Early Stage Epithelial Ovarian Cancer. Cancers, 2020, 12, 2374.	1.7	4
32	Proposal of a Two-Tier System in Grouping Adenocarcinoma of the Uterine Cervix. Cancers, 2020, 12, 1251.	1.7	7
33	Management of Stage IIB Cervical Cancer: an Overview of the Current Evidence. Current Oncology Reports, 2020, 22, 28.	1.8	11
34	Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms. Journal of Gynecologic Oncology, 2020, 31, e18.	1.0	59
35	A retrospective study for investigating the relationship between old and new staging systems with prognosis in ovarian cancer using gynecologic cancer registry of Japan Society of Obstetrics and Gynecology (JSOG): disparity between serous carcinoma and clear cell carcinoma. Journal of Gynecologic Oncology, 2020, 31, e45.	1.0	7
36	Lymphadenectomy for primary ovarian cancer: a systematic review and meta-analysis. Journal of Gynecologic Oncology, 2020, 31, e67.	1.0	19

3

#	Article	IF	CITATIONS
37	Involvement of the MDR1 gene and glycolipids in anticancer drug-resistance of human ovarian carcinoma-derived cells. Human Cell, 2019, 32, 447-452.	1.2	5
38	Value and limitation of conization as a diagnostic procedure for cervical neoplasm. Journal of Obstetrics and Gynaecology Research, 2019, 45, 2419-2424.	0.6	6
39	Significance of Malignant Peritoneal Cytology on the Survival of Women with Early-Stage Cervical Cancer: A Japanese Gynecologic Oncology Group Study. Journal of Clinical Medicine, 2019, 8, 1822.	1.0	5
40	Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer. Gynecologic Oncology, 2019, 155, 39-50.	0.6	16
41	Neoadjuvant Chemotherapy with Taxane and Platinum Followed by Radical Hysterectomy for Stage IB2-IIB Cervical Cancer: Impact of Histology Type on Survival. Journal of Clinical Medicine, 2019, 8, 156.	1.0	12
42	Comprehensive Serum Glycopeptide Spectra Analysis (CSGSA): A Potential New Tool for Early Detection of Ovarian Cancer. Cancers, 2019, 11, 591.	1.7	9
43	Multidisciplinary perspectives on newly revised 2018 FIGO staging of cancer of the cervix uteri. Journal of Gynecologic Oncology, 2019, 30, e40.	1.0	31
44	Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: A JSGO–JSOG joint study. Gynecologic Oncology, 2019, 153, 589-596.	0.6	74
45	Predictors for pathological parametrial invasion in clinical stage IIB cervical cancer. European Journal of Surgical Oncology, 2019, 45, 1417-1424.	0.5	10
46	Intraoperative Capsule Rupture, Postoperative Chemotherapy, and Survival of Women With Stage I Epithelial Ovarian Cancer. Obstetrics and Gynecology, 2019, 134, 1017-1026.	1.2	43
47	Association of Radical Hysterectomy Surgical Volume and Survival for Early-Stage Cervical Cancer. Obstetrics and Gynecology, 2019, 133, 1086-1098.	1.2	77
48	Changes in the Clinicopathological Demographics of Vulvar Cancer in Japan: Increasing Oldest-Old, Stage Shifting, and Decreasing Cohort-Level Survival â€. Journal of Clinical Medicine, 2019, 8, 2081.	1.0	9
49	Association of statins, aspirin, and venous thromboembolism in women with endometrial cancer. Gynecologic Oncology, 2019, 152, 605-611.	0.6	4
50	Profile of treatment-related complications in women with clinical stage IB-IIB cervical cancer: A nationwide cohort study in Japan. PLoS ONE, 2019, 14, e0210125.	1.1	15
51	Validation of the 2018 FIGO cervical cancer staging system. Gynecologic Oncology, 2019, 152, 87-93.	0.6	203
52	Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer. International Journal of Clinical Oncology, 2019, 24, 1-19.	1.0	106
53	Neoadjuvant chemotherapy for epithelial ovarian cancer in Japan: a JSGO-JSOG joint study. Journal of Gynecologic Oncology, 2019, 30, e113.	1.0	3
54	Role of Para-aortic Lymphadenectomy During Radical Hysterectomy for Stage IB–IIB Cervical Cancer. Comprehensive Gynecology and Obstetrics, 2019, , 183-207.	0.0	0

#	Article	IF	CITATIONS
55	Significance of abnormal peritoneal cytology on survival of women with stage l–II endometrioid endometrial cancer. Gynecologic Oncology, 2018, 149, 301-309.	0.6	43
56	Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067). Gynecologic Oncology, 2018, 149, 513-519.	0.6	26
57	Fully sialylated alpha-chain of complement 4-binding protein (A2160): a novel prognostic marker for epithelial ovarian carcinoma. Archives of Gynecology and Obstetrics, 2018, 297, 749-756.	0.8	3
58	UPLCâ€MS/MS based diagnostics for epithelial ovarian cancer using fully sialylated C4â€binding protein. Biomedical Chromatography, 2018, 32, e4180.	0.8	3
59	Intrauterine Manipulator Use During Minimally Invasive Hysterectomy and Risk of Lymphovascular Space Invasion in Endometrial Cancer. International Journal of Gynecological Cancer, 2018, 28, 208-219.	1.2	28
60	Identifying a candidate population for ovarian conservation in young women with clinical stage IB–IIB cervical cancer. International Journal of Cancer, 2018, 142, 1022-1032.	2.3	28
61	Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer. International Journal of Clinical Oncology, 2018, 23, 201-234.	1.0	47
62	The use of conization to identify and treat severe lesions among prediagnosed CIN1 and 2 patients in Japan. Journal of Gynecologic Oncology, 2018, 29, e46.	1.0	7
63	The Clinical Features of Recurrent Endometrial Cancer in Japan: Chemotherapy Instead of Radiotherapy as Postoperative Adjuvant Treatment. International Journal of Gynecological Cancer, 2018, 28, 1616-1623.	1.2	9
64	Impact of institutional accreditation by the Japan Society of Gynecologic Oncology on the treatment and survival of women with cervical cancer. Journal of Gynecologic Oncology, 2018, 29, e23.	1.0	18
65	Quality and quantity metrics of pelvic lymph node metastasis and risk of para-aortic lymph node metastasis in stage IB–IIB cervical cancer. Journal of Gynecologic Oncology, 2018, 29, e10.	1.0	13
66	Trends in single women with malignancy of the uterine cervix in United States. Journal of Gynecologic Oncology, 2018, 29, e24.	1.0	7
67	Characteristics and outcomes of reproductive-aged women with early-stage cervical cancer: trachelectomy vs hysterectomy. American Journal of Obstetrics and Gynecology, 2018, 219, 461.e1-461.e18.	0.7	22
68	Quality indicators for cervical cancer care in Japan. Journal of Gynecologic Oncology, 2018, 29, e83.	1.0	14
69	Trachelectomy for stage IB1 cervical cancer with tumor size >2 cm: trends and characteristics in the United States. Journal of Gynecologic Oncology, 2018, 29, e85.	1.0	11
70	Risk stratification models for para-aortic lymph node metastasis and recurrence in stage IB–IIB cervical cancer. Journal of Gynecologic Oncology, 2018, 29, e11.	1.0	34
71	Comparison of adjuvant therapy for nodeâ€positive clinical stage IBâ€IB cervical cancer: Systemic chemotherapy <i>versus</i> pelvic irradiation. International Journal of Cancer, 2017, 141, 1042-1051.	2.3	59
72	The concept of platinum sensitivity could be applied to recurrent cervical cancer: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group. Cancer Chemotherapy and Pharmacology, 2017, 80, 697-705.	1.1	7

#	Article	IF	CITATIONS
73	Ovarian conservation for young women with clinical stage IB–IIB cervical cancer in Japan. Journal of Gynecologic Oncology, 2017, 28, e60.	1.0	8
74	Opportunistic bilateral salpingectomy during benign gynecological surgery for ovarian cancer prevention: a survey of Gynecologic Oncology Committee of Japan Society of Obstetrics and Gynecology. Journal of Gynecologic Oncology, 2017, 28, e52.	1.0	5
75	Assessing the effect of guideline introduction on clinical practice and outcome in patients with endometrial cancer in Japan: a project of the Japan Society of Gynecologic Oncology (JSGO) guideline evaluation committee. Journal of Gynecologic Oncology, 2017, 28, e76.	1.0	27
76	Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer. Oncotarget, 2017, 8, 106866-106875.	0.8	30
77	Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan. Journal of Gynecologic Oncology, 2016, 27, e29.	1.0	23
78	Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer. International Journal of Clinical Oncology, 2016, 21, 435-446.	1.0	57
79	Japan Society of Gynecologic Oncology guidelines 2013 for the treatment of uterine body neoplasms. International Journal of Clinical Oncology, 2016, 21, 419-434.	1.0	36
80	Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial. Journal of Clinical Oncology, 2016, 34, 2881-2887.	0.8	114
81	Association of Low-Dose Aspirin and Survival of Women With Endometrial Cancer. Obstetrics and Gynecology, 2016, 128, 127-137.	1.2	39
82	Enhanced expression of unique gangliosides with GM2-determinant in human uterine cervical carcinoma-derived cell lines. Glycoconjugate Journal, 2016, 33, 745-754.	1.4	8
83	Japan Society of Gynecologic Oncology guidelines 2011 for the treatment of uterine cervical cancer. International Journal of Clinical Oncology, 2015, 20, 240-248.	1.0	104
84	Fully-sialylated alpha-chain of complement 4-binding protein: Diagnostic utility for ovarian clear cell carcinoma. Gynecologic Oncology, 2015, 139, 520-528.	0.6	17
85	Role of lymphadenectomy for ovarian cancer. Journal of Gynecologic Oncology, 2014, 25, 279.	1.0	27
86	Novel Glycobiomarker for Ovarian Cancer That Detects Clear Cell Carcinoma. Journal of Proteome Research, 2014, 13, 1624-1635.	1.8	34
87	Surgical Principles for Managing Stage IB2, IIA2, and IIB Uterine Cervical Cancer (Bulky Tumors) in Japan: A Survey of the Japanese Gynecologic Oncology Group. International Journal of Gynecological Cancer, 2014, 24, 1333-1340.	1.2	42
88	Current Surgical Principle for Uterine Cervical Cancer of Stages Ia2, Ib1, and IIa1 in Japan: A Survey of the Japanese Gynecologic Oncology Group. International Journal of Gynecological Cancer, 2013, 23, 1655-1662.	1.2	14
89	Isolated Tubal Torsion in Adolescence: Case Report and Review. Journal of Gynecologic Surgery, 2013, 29, 39-44.	0.0	0
90	Retroperitoneal mature cystic teratoma resected by laparoscopic surgery: A case report. Japanese Journal of Gynecologic and Obstetric Endoscopy, 2012, 28, 556-560.	0.0	0

#	Article	IF	CITATIONS
91	Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 edition. International Journal of Clinical Oncology, 2010, 15, 531-542.	1.0	44
92	Phase I Study of Combination Chemotherapy Using Irinotecan Hydrochloride and Nedaplatin for Advanced or Recurrent Cervical Cancer. Oncology, 2003, 65, 102-107.	0.9	11
93	Flow cytometric analysis of cell surface antigen recognized by monoclonal antibody (MSN-1) in normal, hyperplasia, and carcinoma of endometrial cells: Its diagnostic value for endometrial carcinoma., 1997, 30, 23-27.		1
94	Biochemical Analysis of Glycosphingolipids in Murine Uterus and Human Uterine Endometrium with Special Reference to the Sexual Cycle Keio Journal of Medicine, 1991, 40, 82-89.	0.5	4